menu
    • menu
    [{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Defender Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"DPI-386","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Defender Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Defender Pharmaceuticals"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"National Aeronautics and Space Administration","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"USAMMDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Defender Pharmaceuticals \/ USAMMDA","highestDevelopmentStatusID":"5","companyTruncated":"Defender Pharmaceuticals \/ USAMMDA"}]

    Find Clinical Drug Pipeline Developments & Deals by Defender Pharmaceuticals

    Menu

    Defender Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Defender Pharmaceuticals Gets Complete Response Letter from FDA for Intranasal Scopolamine

                            Details : DPI-386 (scopolamine hydrobromide) is a mAChRs inhibitor which is being evaluated in phase 3 clinical trials for the treatment of motion sickness in adults.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 30, 2024

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : National Aeronautics and Space Administration

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Defender Pharmaceuticals Announces Collaboration with NASA on Two Phase 2 Clinical Trials Investigating DPI-38...

                            Details : DPI-386 (scopolamine hydrobromide) intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 24, 2023

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : National Aeronautics and Space Administration

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Accepts Defender Pharmaceuticals™ New Drug Application for Intranasal Scopolamine Gel

                            Details : DPI-386 (scopolamine hydrobromide) intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 26, 2023

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : USAMMDA

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Defender Pharmaceuticals Announces Exclusive License Agreement with the U.S. Army for the Development of Produ...

                            Details : Under the agreement, Defender Pharmaceuticals will develop and commercialize 8 products against the following tropical diseases: tularemia, Venezuelan Equine Encephalitis, Eastern Equine Encephalitis, Western Equine Encephalitis, Rift Valley Fever, chiku...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 31, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : USAMMDA

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Defender Pharmaceuticals Announces Submission of New Drug Application to FDA with Intranasal Scopolamine for P...

                            Details : DPI-386 (scopolamine hydrobromide) intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2023

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III Clinical Trial of Intranasal Scopolam...

                            Details : DPI-386 (scopolamine hydrobromide) Intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 05, 2023

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DPI-386

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Repurposed Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

                            Details : DPI-386 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Motion Sickness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 01, 2021

                            Lead Product(s) : DPI-386

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Repurposed Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth